All Stories

  1. Circulating Activin A, FSTL3 and BMP9 in asymptomatic BMPR2 pathogenic-variant carriers
  2. Association between Birt-Hogg-Dubé syndrome and Pulmonary Hypertension: a case series
  3. Placental Growth Factor Promotes Endothelial Activation and Inflammatory Remodelling in Pulmonary Hypertension
  4. Pulmonary arterial hypertension with signs of venous/capillary involvement in connective tissue diseases: paradigms and paradoxes
  5. Effective Arterial Elastance Relates More Closely to Pulsatile Than Resistive Indices During Routine Hemodynamic Assessment of Inoperable CTEPH
  6. Circulating Biomarker Results From a Phase 2 Study of Seralutinib in Pulmonary Arterial Hypertension
  7. Multimodal investigation of the association between bevacizumab and pulmonary arterial hypertension
  8. Bridging Disciplines in Portopulmonary Hypertension: A Multidisciplinary Call for Harmonized Patient Management
  9. Chronic thromboembolic pulmonary hypertension associated with venous thoracic outlet syndrome: a retrospective case series
  10. Correspondence on: Pulmonary arterial hypertension in adults with Still’s disease: another pulmonary manifestation associated with HLA-DRB1*15–reply
  11. Response to correspondence on: Pulmonary arterial hypertension in adults with Still's disease: another pulmonary manifestation associated with HLA-DRB1*15
  12. Safety and Efficacy of upfront triple therapy including parenteral treprostinil compared to double oral therapy in PAH (TripleTRE): study protocol for a randomized trial
  13. Seralutinib for the Treatment of Pulmonary Arterial Hypertension in Adults: TORREY Open-Label Extension Study
  14. Clustering Patients with Pulmonary Hypertension Using the Plasma Proteome
  15. The Activin Pathway in Chronic Thromboembolic Pulmonary Hypertension: A Potential Biomarker for Residual Pulmonary Hypertension After Endarterectomy
  16. Diuretic adherence in patients with precapillary pulmonary hypertension: insights from the PHARE study
  17. Drugs targeting novel pathways in pulmonary arterial hypertension
  18. Risk stratification in Eisenmenger syndrome
  19. ERS Congress 2024: highlights from the Pulmonary Vascular Diseases Assembly
  20. Effect of Balloon Pulmonary Angioplasty and Riociguat on Right Ventricular Afterload and Function in CTEPH: Insights From the RACE Trial
  21. Changes in REVEAL Lite 2 risk status are associated with long-term outcomes in patients with pulmonary arterial hypertension: A post-hoc analysis of the GRIPHON study
  22. Effect of sotatercept on circulating proteomics in pulmonary arterial hypertension
  23. Thirty years of surgical management of pediatric pulmonary hypertension: Mid-term outcomes following reverse Potts shunt and transplantation
  24. Treatment algorithm for pulmonary arterial hypertension
  25. Medication adherence, related factors and outcomes among patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension: a systematic review
  26. Risk Assessment in Pulmonary Veno-Occlusive Disease: The First Step Towards Future Trials?
  27. Percutaneous atrial septal defect closure in patients with pulmonary arterial hypertension
  28. POINT: Should the Use of Upfront Triple Combination Therapy Be Standard of Care in Pulmonary Arterial Hypertension? Yes
  29. Pulmonary veno-occlusive disease: illustrative cases and literature review
  30. The Management of Pulmonary Arterial Hypertension in the Setting of Systemic Sclerosis
  31. From the microscopic to the macroscopic: clinical–radiological–pathological correlation in pulmonary hypertension
  32. ERS International Congress 2023: highlights from the Pulmonary Vascular Diseases Assembly
  33. Sequential multimodal therapy in chronic thromboembolic pulmonary hypertension with mixed anatomical lesions: a proof of concept
  34. Pulmonary arterial hypertension
  35. Diagnosis and management of pulmonary veno-occlusive disease
  36. New trends in pulmonary hypertension
  37. Reply to Jha
  38. The Influence of Methods for Cardiac Output Determination on the Diagnosis of Precapillary Pulmonary Hypertension: A Mathematical Model
  39. To be or not to be… treated with initial combination therapy, that is the (PAH) question
  40. Erythrocytes are altered in pulmonary arterial hypertension
  41. ERS statement on chronic thromboembolic pulmonary hypertension
  42. Sequential combination therapy with parenteral prostacyclin in BMPR2 mutations carriers
  43. Reply to Jin et al. and to Sun et al.
  44. Sex and gender in pulmonary arterial hypertension
  45. Outcomes of patients with decreased arterial oxyhaemoglobin saturation on pulmonary arterial hypertension drugs
  46. The isobaric pulmonary arterial compliance in pulmonary hypertension
  47. Pulmonary Vascular Resistance in Pulmonary Arterial Hypertension: La Pièce de Résistance?
  48. Initial triple therapy in pulmonary arterial hypertension: coming of age and rejuvenated
  49. Reply to: “Management of portopulmonary hypertension: What is more important, PAH severity or liver disease severity?”
  50. ERS statement on chronic thromboembolic pulmonary hypertension
  51. Reversible pulmonary hypertension associated with multivisceral Whipple's disease
  52. Long-term outcomes with initial triple oral therapy in pulmonary arterial hypertension (PAH): Insights from TRITON
  53. Pulmonary Hypertension Complicating Pulmonary Artery Involvement in Pseudoxanthoma Elasticum
  54. Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors
  55. Severe Pulmonary Hypertension Management Across Europe (PHAROS): an ERS Clinical Research Collaboration
  56. Initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension
  57. Transition from intravenous epoprostenol to selexipag in pulmonary arterial hypertension: a word of caution
  58. Pulmonary arterial hypertension registries: past, present and into the future
  59. Intensity and quality of exertional dyspnoea in patients with stable pulmonary hypertension
  60. A dynamic prognostic model to predict survival and determine treatment goals in pulmonary arterial hypertension (PAH): the EFORT study
  61. Assembly 13: placing the pulmonary circulation in the heart of ERS
  62. Highlights from the ERS International Congress 2018: Assembly 13 – Pulmonary Vascular Diseases
  63. Clinical trial design and new therapies for pulmonary arterial hypertension
  64. Hépatopathies et maladies vasculaires pulmonaires
  65. Clinical and Hemodynamic Correlates of Pulmonary Arterial Stiffness in Incident, Untreated Patients With Idiopathic Pulmonary Arterial Hypertension
  66. Association Between BMI and Obesity With Survival in Pulmonary Arterial Hypertension
  67. Impact of the initiation of balloon pulmonary angioplasty program on referral of patients with chronic thromboembolic pulmonary hypertension to surgery
  68. Risk stratification in pulmonary arterial hypertension
  69. Évaluation de l’IRM cardiaque dans le suivi des patients ayant une hypertension artérielle pulmonaire (EVITA). IRM cardiaque dans le suivi de l’hypertension artérielle pulmonaire
  70. Pulmonary hypertension associated with neurofibromatosis type 1
  71. Natural History over 8 Years of Pulmonary Vascular Disease in a Patient Carrying Biallelic EIF2AK4 Mutations
  72. Pharmacovigilance in a rare disease: example of the VIGIAPATH program in pulmonary arterial hypertension
  73. Portopulmonary hypertension
  74. Factors predicting outcome after pulmonary endarterectomy
  75. Genetic determinants of risk and survival in pulmonary arterial hypertension
  76. Clinical phenotypes and survival of pre-capillary pulmonary hypertension in systemic sclerosis
  77. Age, risk and outcomes in idiopathic pulmonary arterial hypertension
  78. Pulmonary vascular remodeling patterns and expression of general control nonderepressible 2 (GCN2) in pulmonary veno-occlusive disease
  79. The Low-Risk Profile in Pulmonary Arterial Hypertension. Time for a Paradigm Shift to Goal-oriented Clinical Trial Endpoints?
  80. Outcome of Portopulmonary Hypertension After Liver Transplantation
  81. Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: Data from the randomized SERAPHIN trial
  82. Risk assessment in pulmonary arterial hypertension
  83. Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI 2 ) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) study
  84. Prognostic Value of Follow-Up Hemodynamic Variables After Initial Management in Pulmonary Arterial Hypertension
  85. RV Fractional Area Change and TAPSE as Predictors of Severe Right Ventricular Dysfunction in Pulmonary Hypertension: A CMR Study
  86. Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality
  87. La maladie veino-occlusive pulmonaire
  88. Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study
  89. Association between Rheumatoid Arthritis and Pulmonary Hypertension: Data from the French Pulmonary Hypertension Registry
  90. Pulmonary Arterial Hypertension Associated With Systemic Lupus Erythematosus
  91. Acute decompensated pulmonary hypertension
  92. Dead-space ventilation is linked to exercise capacity and survival in distal chronic thromboembolic pulmonary hypertension
  93. Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension
  94. Medical Treatment of Pulmonary Arterial Hypertension
  95. Portopulmonary Hypertension
  96. Exertional dyspnoea in pulmonary arterial hypertension
  97. Are indexed values better for defining exercise pulmonary hypertension?
  98. Plasma proteome analysis in patients with pulmonary arterial hypertension: an observational cohort study
  99. Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension
  100. Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension
  101. Impact of High-Priority Allocation on Lung and Heart-Lung Transplantation for Pulmonary Hypertension
  102. Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study
  103. Validation of a risk assessment instrument for pulmonary arterial hypertension
  104. Pulmonary hypertension due to left heart disease
  105. Outcome of adults with Eisenmenger syndrome treated with drugs specific to pulmonary arterial hypertension: A French multicentre study
  106. Long-term outcomes of pulmonary arterial hypertension under specific drug therapy in Eisenmenger syndrome
  107. Ambrisentan use for pulmonary arterial hypertension in a post-authorization drug registry: The VOLibris Tracking Study
  108. Long-term outcome in liver transplantation candidates with portopulmonary hypertension
  109. Gut–Lung Connection in Pulmonary Arterial Hypertension
  110. SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension
  111. Clinical phenotypes and outcomes of heritable and sporadic pulmonary veno-occlusive disease: a population-based study
  112. Epoprostenol and pulmonary arterial hypertension: 20 years of clinical experience
  113. Macitentan Improves Health-Related Quality of Life for Patients With Pulmonary Arterial Hypertension
  114. Proceedings of Réanimation 2017, the French Intensive Care Society International Congress
  115. A Clinical and Echocardiographic Score to Identify Pulmonary Hypertension Due to HFpEF
  116. Beyond a single pathway: combination therapy in pulmonary arterial hypertension
  117. BMPR2mutation status influences bronchial vascular changes in pulmonary arterial hypertension
  118. Deterioration of pulmonary hypertension and pleural effusion with bosutinib following dasatinib lung toxicity
  119. Interferon-induced pulmonary hypertension
  120. Pulmonary arterial hypertension in idiopathic inflammatory myopathies
  121. Non-invasive diagnosis of pulmonary hypertension from lung Doppler signal: a proof of concept study
  122. Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension
  123. Direct-Acting Antiviral Medications for Hepatitis C Virus Infection and Pulmonary Arterial Hypertension
  124. International Liver Transplant Society Practice Guidelines
  125. Regulatory T Cell Dysfunction in Idiopathic, Heritable and Connective Tissue-Associated Pulmonary Arterial Hypertension
  126. Lung capillary blood volume and membrane diffusion in precapillary pulmonary hypertension
  127. Response to Letter Regarding Article, “Mitomycin-Induced Pulmonary Veno-Occlusive Disease: Evidence From Human Disease and Animal Model”
  128. Diagnostic concordance of different criteria for exercise pulmonary hypertension in subjects with normal resting pulmonary artery pressure
  129. Pulmonary veno-occlusive disease
  130. Initial dual oral combination therapy in pulmonary arterial hypertension
  131. Resting pulmonary artery pressure of 21–24 mmHg predicts abnormal exercise haemodynamics
  132. A rare case of sarcoidosis-associated pulmonary hypertension in a patient exposed to silica
  133. Patients’, relatives’, and practitioners’ views of pulmonary arterial hypertension: A qualitative study
  134. BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis
  135. Loss of Vascular Distensibility During Exercise Is an Early Hemodynamic Marker of Pulmonary Vascular Disease
  136. Comparative Safety and Tolerability of Prostacyclins in Pulmonary Hypertension
  137. Kinetics of Cardiac Output at the Onset of Exercise in Precapillary Pulmonary Hypertension
  138. Infections liées aux cathéters veineux centraux tunnélisés chez les patients ayant une hypertension artérielle pulmonaire traitée par prostacycline intraveineuse
  139. Selexipag for the Treatment of Pulmonary Arterial Hypertension
  140. Genetic counselling in a national referral centre for pulmonary hypertension
  141. Usefulness of Cardiovascular Magnetic Resonance Indices to Rule In or Rule Out Precapillary Pulmonary Hypertension
  142. Chronic thromboembolic pulmonary hypertension
  143. Pulmonary arterial hypertension in patients treated with interferon: TABLE 1
  144. Occupational exposure to organic solvents: a risk factor for pulmonary veno-occlusive disease
  145. Pulmonary Hypertension Complicating Fibrosing Mediastinitis
  146. Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN
  147. The 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: a practical chronicle of progress
  148. Response to Letter Regarding Article, “Advances in Therapeutic Interventions for Patients With Pulmonary Arterial Hypertension”
  149. Mitomycin-Induced Pulmonary Veno-Occlusive Disease
  150. A prospective study of the 6 min walk test as a surrogate marker for haemodynamics in two independent cohorts of treatment-naïve systemic sclerosis-associated pulmonary arterial hypertension
  151. New pharmacotherapy options for pulmonary arterial hypertension
  152. Non-Invasive Determination of Cardiac Output in Pre-Capillary Pulmonary Hypertension
  153. Nasal decongestant exposure in patients with pulmonary arterial hypertension: a pilot study: TABLE 1
  154. Criteria for diagnosis of exercise pulmonary hypertension
  155. Characteristics of Pulmonary Arterial Hypertension in Affected Carriers of a Mutation Located in the Cytoplasmic Tail of Bone Morphogenetic Protein Receptor Type 2
  156. Inspiratory muscle function, dynamic hyperinflation and exertional dyspnoea in pulmonary arterial hypertension
  157. Validation of two predictive models for survival in pulmonary arterial hypertension
  158. Systolic and Mean Pulmonary Artery Pressures
  159. Relation between left ventricular ejection time and pulmonary hemodynamics in pulmonary hypertension
  160. Chemotherapy-Induced Pulmonary Hypertension
  161. Effect of Macitentan on Hospitalizations
  162. Advances in Therapeutic Interventions for Patients With Pulmonary Arterial Hypertension
  163. Connective tissue disease associated with pulmonary arterial hypertension: management of a patient with severe haemodynamic impairment
  164. Pulmonary arterial hypertension
  165. Clinical Pharmacology of Endothelin Receptor Antagonists Used in the Treatment of Pulmonary Arterial Hypertension
  166. Pulmonary arterial hypertension in patients treated with interferon
  167. Lung and heart-lung transplantation for systemic sclerosis patients. A monocentric experience of 13 patients, review of the literature and position paper of a multidisciplinary Working Group
  168. Hypertension pulmonaire et maladies hépatiques
  169. Traitement chirurgical de l’hypertension pulmonaire post-embolique
  170. Traitement de l’hypertension artérielle pulmonaire
  171. Mechanisms of exertional dyspnoea in pulmonary veno-occlusive disease with EIF2AK4 mutations
  172. Long-term sildenafil added to intravenous epoprostenol in patients with pulmonary arterial hypertension
  173. Prognostic value of exercise pulmonary haemodynamics in pulmonary arterial hypertension
  174. The potential for macitentan, a new dual endothelin receptor antagonist, in the treatment of pulmonary arterial hypertension
  175. Current epoprostenol use in patients with severe idiopathic, heritable or anorexigen-associated pulmonary arterial hypertension: Data from the French pulmonary hypertension registry
  176. Biomarkers for the prognosis of pulmonary arterial hypertension: Holy grail or flying circus?
  177. Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study
  178. EPITOME-2: An open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension
  179. Right heart failure: Toward a common language
  180. Targeted therapies in pulmonary arterial hypertension
  181. EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension
  182. Treatment Goals of Pulmonary Hypertension
  183. Proinflammatory cytokine levels are linked to death in pulmonary arterial hypertension
  184. Left Ventricular Ejection Time in Acute Heart Failure Complicating Precapillary Pulmonary Hypertension
  185. Pulmonary arterial hypertension in familial hemiplegic migraine with ATP1A2 channelopathy
  186. Inflammatory Mechanisms in HIV-Associated Pulmonary Arterial Hypertension
  187. Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension
  188. Pharmacokinetic evaluation of sildenafil as a pulmonary hypertension treatment
  189. Pulmonary arterial hypertension
  190. Calcium-Channel Blockers in Pulmonary Arterial Hypertension
  191. Pathways in pulmonary arterial hypertension: the future is here
  192. Survival in systemic sclerosis-associated pulmonary arterial hypertension in the modern management era
  193. Independent Association of Urinary F2-Isoprostanes With Survival in Pulmonary Arterial Hypertension
  194. Pulmonary veno-occlusive disease and pulmonary capillary haemangiomatosis
  195. Hemodynamics in Pulmonary Arterial Hypertension: Current and Future Perspectives
  196. The study of risk in pulmonary arterial hypertension
  197. Treat-to-target approach in pulmonary arterial hypertension: a consensus-based proposal
  198. Computed tomography findings of pulmonary venoocclusive disease in scleroderma patients presenting with precapillary pulmonary hypertension
  199. Renal Replacement Therapy in Patients with Severe Precapillary Pulmonary Hypertension with Acute Right Heart Failure
  200. Out-of-Proportion Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction
  201. Dynamic respiratory mechanics and exertional dyspnoea in pulmonary arterial hypertension
  202. EBUS-TBNA in the differential diagnosis of pulmonary artery sarcoma and thromboembolism: Figure 1–
  203. Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertension
  204. Pulmonary Arterial Hypertension in Patients Treated by Dasatinib
  205. Mediastinal Fibrosis Mimicking Proximal Chronic Thromboembolic Disease
  206. Pulmonary hypertension associated with benfluorex exposure
  207. Portopulmonary Hypertension
  208. L’hypertension artérielle pulmonaire associée au VIH
  209. Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: An observational study
  210. Portopulmonary Hypertension and Hepatopulmonary Syndrome
  211. Optimal management of severe pulmonary arterial hypertension
  212. Systemic lupus erythematosus-associated PAH: is targeting inflammation the key to success?
  213. Ventilation/perfusion lung scan in pulmonary veno-occlusive disease
  214. Screening for pulmonary arterial hypertension in patients with systemic sclerosis: Clinical characteristics at diagnosis and long-term survival
  215. Pulmonary Arterial Hypertension in a Patient With Cowden Syndrome and Anorexigen Exposure
  216. Systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease: Impact of pulmonary arterial hypertension therapies
  217. Treatment of pulmonary arterial hypertension with targeted therapies
  218. The association between resting and mild-to-moderate exercise pulmonary artery pressure
  219. Pulmonary hypertension related to appetite suppressants
  220. Pulmonary Hypertension in Patients With Neurofibromatosis Type I
  221. Endothelin receptor antagonists for the treatment of pulmonary arterial hypertension
  222. Prise en charge de l’hypertension artérielle pulmonaire en 2011 : les innovations depuis les recommandations ERS/ESC 2009
  223. Pulmonary veno-occlusive disease: The bête noire of pulmonary hypertension in connective tissue diseases?
  224. Current management approaches to portopulmonary hypertension
  225. Pulmonary arterial hypertension: combination therapy in the modern management era
  226. Treat-to-target strategies in pulmonary arterial hypertension: the importance of using multiple goals
  227. Pharmacokinetic evaluation of continuous intravenous epoprostenol
  228. Effects of HIV Protease Inhibitors on Progression of Monocrotaline- and Hypoxia-Induced Pulmonary Hypertension in Rats
  229. Evidence for the use of combination targeted therapeutic approaches for the management of pulmonary arterial hypertension
  230. Pulmonary veno-occlusive disease: Recent progress and current challenges
  231. Survival in Patients With Idiopathic, Familial, and Anorexigen-Associated Pulmonary Arterial Hypertension in the Modern Management Era
  232. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension
  233. Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension
  234. Absence of influence of gender and BMPR2 mutation type on clinical phenotypes of pulmonary arterial hypertension
  235. Objectifs thérapeutiques dans l’hypertension artérielle pulmonaire
  236. Characterization of Pulmonary Arterial Hypertension Patients Walking More Than 450 m in 6 Min at Diagnosis
  237. Assessing effectiveness of pulmonary arterial hypertension therapies in daily practice
  238. Clinical Outcomes of Pulmonary Arterial Hypertension in Patients Carrying anACVRL1(ALK1) Mutation
  239. Pulmonary arterial hypertension associated with systemic sclerosis in patients with functional class II dyspnoea: mild symptoms but severe outcome
  240. Diagnostic et prise en charge de l’hypertension pulmonaire en 2009. Commentaires sur les nouvelles recommandations de l’European Society of Cardiology (ESC) et de l’European Respiratory Society (ERS)
  241. HIV-associated pulmonary arterial hypertension: survival and prognostic factors in the modern therapeutic era
  242. Maladie veino-occlusive et hémangiomatose capillaire pulmonaire
  243. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil
  244. Implementing the ESC/ERS pulmonary hypertension guidelines: real-life cases from a national referral centre
  245. Prognostic factors of acute heart failure in patients with pulmonary arterial hypertension
  246. Noncardiothoracic nonobstetric surgery in mild-to-moderate pulmonary hypertension
  247. Is Pulmonary Arterial Hypertension Really a Late Complication of Systemic Sclerosis?
  248. Goal-oriented therapy in pulmonary veno-occlusive disease: a word of caution
  249. Pulmonary Venoocclusive Disease and Failure of Specific Therapy
  250. Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension
  251. Fatal dissection of the pulmonary artery in pulmonary arterial hypertension
  252. Idiopathic Pulmonary Arterial Hypertension and Pulmonary Veno-occlusive Disease: Similarities and Differences
  253. Pulmonary Arterial Hypertension and HIV Infection
  254. Intravenous iloprost for pulmonary arterial hypertension: still waiting for evidence
  255. Cautious epoprostenol therapy is a safe bridge to lung transplantation in pulmonary veno-occlusive disease
  256. The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France
  257. End Points and Clinical Trial Design in Pulmonary Arterial Hypertension
  258. Updated Evidence-Based Treatment Algorithm in Pulmonary Arterial Hypertension
  259. Cirrhosis ameliorates monocrotaline-induced pulmonary hypertension in rats
  260. Fenfluramine-like cardiovascular side-effects of benfluorex
  261. Pulmonary veno-occlusive disease
  262. Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension
  263. Addition of Sildenafil to Long-Term Intravenous Epoprostenol Therapy in Patients with Pulmonary Arterial Hypertension
  264. Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinerAIR-Sclerodermie study
  265. Portopulmonary Hypertension
  266. HIV-related pulmonary arterial hypertension: clinical presentation and management
  267. Review: Therapeutic advances in pulmonary arterial hypertension
  268. Pulmonary Veno-Occlusive Disease
  269. Clinical Outcomes of Pulmonary Arterial Hypertension in Carriers ofBMPR2Mutation
  270. Changes in exercise haemodynamics during treatment in pulmonary arterial hypertension
  271. Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases
  272. Immunosuppressive therapy in lupus- and mixed connective tissue disease–associated pulmonary arterial hypertension: A retrospective analysis of twenty-three cases
  273. Prevalence of HIV-related Pulmonary Arterial Hypertension in the Current Antiretroviral Therapy Era
  274. Intravenous Epoprostenol in Inoperable Chronic Thromboembolic Pulmonary Hypertension
  275. Hypertension pulmonaire postembolique
  276. Hypertension artérielle pulmonaire postembolique tumorale
  277. Pulmonary vascular abnormalities in cirrhosis
  278. Rapid Switch From Intravenous Epoprostenol to Intravenous Treprostinil in Patients With Pulmonary Arterial Hypertension
  279. Hypertension portopulmonaire
  280. Cœur pulmonaire chronique postembolique révélant une bêtathalassémie intermédiaire après splénectomie
  281. Bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects
  282. Long term imatinib treatment in pulmonary arterial hypertension
  283. Immunosuppressive Therapy in Connective Tissue Diseases-Associated Pulmonary Arterial Hypertension
  284. Pulmonary Arterial Hypertension in France
  285. Mutations of the TGF-β type II receptorBMPR2 in pulmonary arterial hypertension
  286. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension
  287. Deleterious Effects of β-Blockers on Exercise Capacity and Hemodynamics in Patients With Portopulmonary Hypertension
  288. Heart rate responses during the 6-minute walk test in pulmonary arterial hypertension
  289. Occult alveolar haemorrhage in pulmonary veno-occlusive disease
  290. Clinical Challenges in Pulmonary Hypertension
  291. Pulmonary Endothelin-1 Clearance in Human Pulmonary Arterial Hypertension
  292. Splenectomy and chronic thromboembolic pulmonary hypertension
  293. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol
  294. Reversibility of pulmonary arterial hypertension in HIV/HHV8-associated Castleman's disease
  295. Diagnostic et classification des hypertensions artérielles pulmonaires
  296. Génétique de l’hypertension artérielle pulmonaire: données récentes et applications pratiques
  297. Traitement chirurgical de la maladie thromboembolique pulmonaire chronique
  298. Les traitements de l’hypertension artérielle pulmonaire à l’heure de la T2A. Recommandations du groupe de travail “Maladies vasculaires pulmonaires” de la Société de pneumologie de langue française
  299. Traitement de l’hypertension artérielle pulmonaire
  300. Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis
  301. Hypertension artérielle pulmonaire
  302. Human herpes virus 8 in HIV and non-HIV infected patients with pulmonary arterial hypertension in France
  303. Treatment of pulmonary arterial hypertension with bosentan: from pathophysiology to clinical evidence
  304. Long-Term Response to Calcium Channel Blockers in Idiopathic Pulmonary Arterial Hypertension
  305. Severe Pulmonary Hypertension during Pregnancy
  306. Bosentan therapy for pulmonary arterial hypertension
  307. Survival with first-line bosentan in patients with primary pulmonary hypertension
  308. Évaluation pronostique de biomarqueurs dans l’hypertension artérielle pulmonaire
  309. Bosentan for the Treatment of Human Immunodeficiency Virus–associated Pulmonary Arterial Hypertension
  310. Caractéristiques cliniques, hémodynamiques et génétiques de l’hypertension artérielle pulmonaire familiale
  311. Traitement de l'hypertension artérielle pulmonaire
  312. Treatment of Pulmonary Arterial Hypertension
  313. Pulmonary Hypertension:CT of the Chest in Pulmonary Venoocclusive Disease
  314. Diagnosis and differential assessment of pulmonary arterial hypertension
  315. Endothelin receptor antagonists in pulmonary arterial hypertension
  316. Prostanoid therapy for pulmonary arterial hypertension
  317. Prise en charge thérapeutique de l’hypertension porto-pulmonaire
  318. Automatic quantification of right ventricular function with gated blood pool SPECT
  319. Chronic thromboembolic pulmonary hypertension
  320. Traitement chirurgical de l’hypertension artérielle pulmonaire post-embolique
  321. Prise en charge thérapeutique de l’hypertension porto-pulmonaire
  322. Novel therapeutic perspectives in pulmonary arterial hypertension
  323. Effects of the Dual Endothelin Receptor Antagonist Bosentan in Patients With Pulmonary Arterial Hypertension
  324. Prognostic Factors for Survival in Human Immunodeficiency Virus–associated Pulmonary Arterial Hypertension
  325. BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives
  326. Primary pulmonary hypertension: Current therapy
  327. Inhaled Iloprost for Severe Pulmonary Hypertension
  328. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension
  329. Pulmonary arterial hypertension and type-I glycogen-storage disease: the serotonin hypothesis
  330. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial
  331. Pulmonary Arterial Hypertension: Thin-Section CT Predictors of Epoprostenol Therapy Failure
  332. Pulmonary Artery Pressure–Flow Relations after Prostacyclin in Primary Pulmonary Hypertension
  333. Hypertension artérielle pulmonaire associée aux connectivites
  334. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study
  335. PATHOBIOLOGY OF PULMONARY HYPERTENSION
  336. RISK FACTORS FOR PULMONARY ARTERIAL HYPERTENSION
  337. Improvement of von Willebrand Factor Proteolysis After Prostacyclin Infusion in Severe Pulmonary Arterial Hypertension
  338. Imbalance between Platelet Vascular Endothelial Growth Factor and Platelet-derived Growth Factor in Pulmonary Hypertension
  339. Severe Pulmonary Hypertension in Histiocytosis X
  340. Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study
  341. Treatment of pulmonary hypertension secondary to connective tissue diseases
  342. Primary Pulmonary Hypertension Associated With the Use of Fenfluramine Derivatives
  343. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension
  344. Treatment of Severe Pulmonary Hypertension Secondary to Connective Tissue Diseases With Continuous IV Epoprostenol (Prostacyclin)
  345. Pulmonary vascular disorders in portal hypertension
  346. Clinical Significance of the Pulmonary Vasodilator Response During Short-term Infusion of Prostacyclin in Primary Pulmonary Hypertension
  347. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension.
  348. Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin.
  349. Pneumopathie aiguë tipidique
  350. Minocycline pneumonitis and eosinophilia. A report on eight patients
  351. Minocycline Pneumonitis and Eosinophilia
  352. Auranofin in steroid dependent asthma.
  353. Prostanoid Treatment for Pulmonary Arterial Hypertension